lymphocyt
import
replic
control
consist
recombin
fusion
protein
contain
clade
b
polrt
nef
formul
adjuv
system
shown
induc
polyfunct
tcell
respons
human
replicationincompet
recombin
antigenexpress
human
adenovir
vector
elicit
highfrequ
antigenspecif
tcell
respons
use
hamper
widespread
preexist
immun
human
serotyp
nonhuman
adenoviru
serotyp
associ
lower
preval
may
offer
altern
strategi
evalu
immunogen
recombin
chimpanze
adenoviru
type
vector
express
clade
b
gag
rt
nef
p
deliv
intramuscularli
homolog
pp
aa
heterolog
aapp
ppaa
primeboost
regimen
macaqu
mice
vaccineinduc
cell
peripher
blood
macaqu
liver
spleen
intestin
genit
mucosa
mice
character
intracellular
cytokin
stain
vaccinespecif
igg
antibodi
macaqu
detect
use
elisa
macaqu
heterolog
primeboost
regimen
induc
polyfunct
persist
balanc
tcell
respons
specif
vaccin
antigen
prime
increas
polyfunction
cell
approxim
memori
cell
exhibit
effectormemori
phenotyp
antibodi
detect
regimen
mice
antigenspecif
tcell
respons
detect
mucos
system
anatom
compart
assess
administ
heterolog
primeboost
regimen
candid
vaccin
act
complementarili
induc
potent
persist
peripher
blood
tcell
respons
antibodi
macaqu
besid
adenovir
vector
prime
modul
plo
one
evid
suggest
lymphocyt
play
critic
role
control
human
immunodefici
viru
type
simian
immunodefici
viru
siv
replic
appear
virusspecif
cell
close
associ
initi
drop
viremia
occur
primari
infect
vaccineinduc
effector
memori
tcell
respons
shown
control
pathogen
replic
rhesu
macaqu
evid
viral
clearanc
addit
appear
invers
relationship
tcell
function
viral
load
particular
cell
shown
implic
mainten
function
memori
cell
qualiti
tcell
respons
seem
crucial
inde
studi
longterm
nonprogressor
hiv
control
reveal
presenc
specif
polyfunct
cell
hivinfect
patient
associ
longterm
nonprogress
diseas
low
viral
load
ultim
object
vaccin
develop
effort
gener
prevent
vaccin
induc
steril
immun
base
protect
antibodi
vaccin
abl
induc
potent
polyfunct
cellmedi
immun
respons
may
also
benefici
control
viral
replic
earli
stage
infect
review
human
adenovir
vectorbas
vaccin
express
siv
antigen
shown
induc
potent
sivspecif
tcell
respons
peripheri
mucos
site
howev
vaccin
regimen
use
replicationdefect
adenoviru
serotyp
vector
alon
primeboost
dna
reduc
acquisit
rate
setpoint
viral
load
clinic
trial
tcell
respons
detect
vaccine
predomin
tcell
respons
whether
insuffici
magnitud
function
breadth
vaccineinduc
cellular
immun
respons
particip
failur
vaccin
provid
demonstr
protect
infect
remain
unclear
particular
step
clinic
trial
preexist
antibodi
titer
appear
neg
impact
tcell
respond
rate
vaccin
develop
nonhuman
primat
nhp
adenovirusderiv
vector
may
present
altern
circumv
preexist
immun
human
adenovirus
preval
neutral
antibodi
nab
nhp
adenovirus
markedli
lower
antihuman
adenoviru
nab
particular
chimpanze
adenoviru
type
thought
circul
minim
human
popul
appear
abl
circumv
crossneutr
preexist
antihuman
adenoviru
antibodi
preval
nab
human
popul
report
low
unit
state
uganda
south
africa
weak
nab
titer
seroposit
detect
replicationincompet
chimpanze
adenovir
vector
shown
elicit
potent
tcell
respons
sever
transgen
mice
nhp
therefor
hypothes
lowseropreval
replicationincompet
chimpanze
adenovir
vector
could
ultim
induc
enhanc
protect
respons
hiv
replic
human
rel
vector
base
human
serotyp
previous
report
candid
vaccin
consist
recombin
fusion
protein
contain
four
clade
b
antigen
gag
pol
revers
transcriptas
rt
nef
gag
adjuv
system
induc
potent
polyfunct
tcell
respons
hivseroneg
volunt
well
patient
antiretrovir
therapi
art
investig
immunogen
heterolog
primeboost
regimen
recombin
vector
express
clade
b
gag
rt
nef
deliv
intramuscularli
rhesu
macaqu
mice
particular
explor
impact
sequenti
administr
two
candid
vaccin
magnitud
memori
phenotyp
function
qualiti
vaccineinduc
peripher
blood
tlymphocyt
respons
nhp
model
subsequ
use
mous
model
character
local
cellmedi
immun
cmi
respons
variou
mucos
system
anatom
compart
immunogen
adjuv
protein
p
andor
recombin
adenovir
vector
administ
homolog
pp
aa
heterolog
aapp
ppaa
primeboost
regimen
evalu
rhesu
macaqu
assess
vaccin
antigenspecif
tcell
humor
respons
peripher
blood
complementari
analysi
use
similar
homolog
heterolog
primeboost
regimen
evalu
local
vaccineinduc
respons
mucos
system
anatom
compart
mous
model
data
individu
anim
present
tabl
primeboost
regimen
induc
polyfunct
tcell
respons
macaqu
tcell
respons
detect
flow
cytometri
first
evalu
immunogen
homolog
primeboost
regimen
two
immun
week
elicit
tcell
respons
vaccin
anim
pp
ppaa
group
geometr
mean
confid
interv
ci
respect
week
two
immun
week
induc
low
bare
detect
tcell
respons
aa
aapp
group
geometr
mean
ci
respect
week
fig
vaccin
candid
tcell
respons
follow
homolog
primeboost
regimen
peak
two
week
second
immun
week
tcell
respons
significantli
higher
p
satterthwait
ttest
contrast
respons
tcell
respons
persist
month
second
immun
week
aa
pp
group
respect
evalu
impact
heterolog
primeboost
regimen
compar
magnitud
tcell
respons
heterolog
booster
immun
anim
prime
two
homolog
vaccin
respons
two
heterolog
booster
immun
anim
significantli
differ
two
immun
anim
aapp
group
week
vs
ppppaa
group
week
p
fig
anim
ppaa
group
priminginduc
respons
initi
declin
peak
week
two
heterolog
booster
immun
given
week
ie
month
second
prime
immun
induc
slight
recal
respons
cytokin
express
profil
circul
cell
character
compar
four
group
week
post
last
immun
week
fig
two
week
second
prime
immun
week
proport
polyfunct
doubleor
triplecytokineexpress
cell
significantli
higher
anim
anim
aa
vs
pp
p
fisher
exact
test
although
total
cytokineexpress
tcell
respons
aa
group
low
geometr
mean
ci
week
pp
group
major
cell
produc
smaller
proport
cell
produc
combin
prime
influenc
cytokin
express
profil
specif
administr
induc
predominantli
cell
singlecytokineexpress
cell
given
anim
pp
group
predominantli
cell
singlecytokineexpress
given
anim
aapp
group
moreov
proport
doubleor
triplecytokineexpress
cell
significantli
higher
two
heterolog
aapp
ppaa
primeboost
regimen
prime
p
aapp
vs
pp
p
ppaa
vs
pp
fisher
exact
test
circul
cell
detect
anim
immun
timepoint
evalu
fig
contrast
first
immun
given
anim
induc
tcell
respons
increas
week
second
immun
two
week
last
dose
cytokin
express
profil
cell
aa
ppaa
aapp
group
significantli
differ
fig
p
fisher
exact
test
major
specif
cell
express
either
alon
combin
cell
data
repres
group
geometr
mean
frequenc
ppaa
group
n
week
n
timepoint
thereaft
dash
line
indic
assay
cutoff
valu
cell
ie
b
cytokin
coexpress
profil
cell
week
post
last
immun
present
primeboost
regimen
data
report
median
frequenc
respond
cell
express
combin
ifnand
tnf
first
third
quartil
measur
pie
chart
repres
group
mean
proport
respond
cell
express
vitro
stimul
one
two
three
cytokin
repres
light
grey
dark
grey
black
respect
among
ifnand
tnf
group
mean
proport
compar
use
fisher
exact
test
signific
level
p
number
center
pie
repres
geometr
mean
total
percentag
cytokineexpress
cell
week
post
last
immun
pbmc
stimul
vitro
overnight
pool
peptid
cover
antigen
sequenc
sever
timepoint
product
ifnand
tnfwa
measur
ic
frequenc
cell
express
percentag
cell
express
andor
andor
candid
vaccin
macaqu
proport
cytokin
express
rtand
nefspecif
cell
among
cytokineexpress
cell
assess
intracellular
cytokin
stain
ic
week
post
last
immun
fig
tcell
respons
mainli
target
rt
nef
irrespect
primeboost
regimen
follow
although
pattern
appear
promin
heterolog
primeboost
group
tcell
respons
also
predominantli
target
rt
low
compar
proport
direct
three
antigen
next
analys
memori
phenotyp
peripher
memori
tcell
respons
month
last
immun
use
memori
marker
costimulatori
molecul
classifi
vaccineelicit
cell
effector
memori
em
central
memori
cm
subset
memori
tcell
respons
induc
primeboost
regimen
compris
mostli
cm
cell
memori
tcell
respons
suggest
balanc
cm
em
phenotyp
fig
although
geometr
mean
frequenc
specif
cell
low
rang
observ
tcell
cytokin
express
profil
compar
seen
week
post
last
vaccin
predominantli
tcell
respons
pp
group
balanc
express
profil
tcell
respons
group
tcell
respons
aa
ppaa
aapp
group
fig
bind
antibodi
respons
assess
elisa
fig
respons
absent
low
group
first
immun
week
geometr
mean
titr
gmt
increas
sharpli
either
second
homolog
immun
gmt
significantli
higher
recipi
recipi
ppppaa
group
week
vs
aappaa
group
week
p
satterthwait
ttest
gmt
also
compar
first
heterolog
immun
anim
one
immun
significantli
boost
gmt
ppaa
group
week
vs
ppppaa
group
week
p
similarli
anim
one
dose
significantli
boost
respons
induc
total
cell
data
repres
group
geometr
mean
frequenc
ppaa
group
n
week
n
timepoint
thereaft
dash
line
indic
assay
cutoff
valu
cell
ie
b
cytokin
coexpress
profil
cell
week
post
last
immun
repres
primeboost
regimen
data
report
median
frequenc
respond
cell
express
combin
ifnand
tnf
first
third
quartil
measur
pie
chart
show
group
mean
proport
respond
cell
express
vitro
stimul
one
two
three
cytokin
repres
light
grey
dark
grey
black
respect
among
ifnand
tnf
group
mean
proport
compar
use
fisher
exact
test
signific
level
p
number
center
pie
repres
geometr
mean
total
percentag
cytokineexpress
cell
week
post
last
immun
magnitud
rtand
nefspecif
tcell
respons
panel
tcell
respons
panel
b
express
ifnandor
tnfwere
assess
week
post
last
immun
use
ic
pbmc
stimul
vitro
overnight
pool
peptid
cover
rt
nef
sequenc
individu
data
box
plot
show
median
upper
lower
interquartil
minimum
maximum
valu
repres
group
pie
chart
show
mean
proport
cell
specif
nef
rt
repres
light
grey
medium
grey
dark
grey
black
respect
number
center
pie
repres
geometr
mean
total
percentag
cytokineexpress
cell
week
post
last
immun
higher
respons
rel
observ
prime
anim
aapp
group
week
vs
ppppaa
group
week
p
group
gmt
declin
peak
time
persist
least
six
month
last
immun
highest
respons
gmt
observ
anim
boost
ppaa
group
week
highfrequ
respons
cell
system
mucos
tissu
mice
last
sought
determin
anatom
local
vaccineinduc
tcell
respons
one
week
post
last
immun
use
mous
model
mice
immun
follow
homolog
pp
aa
heterolog
aapp
ppaa
primeboost
regimen
receiv
salin
control
evalu
magnitud
cytokin
produc
tcell
respons
liver
spleen
well
mucosa
genit
tract
small
intestin
due
small
number
data
point
compar
statist
analys
group
perform
tcell
respons
observ
experi
nhp
model
describ
respons
observ
mice
vaccin
specif
cytokineexpress
andor
cell
detect
compart
assess
highest
frequenc
found
genit
tract
mucosa
fig
tcell
respons
detect
control
group
tcell
respons
observ
spleen
liver
genit
tract
anim
immun
pp
aapp
ppaa
regimen
aapp
regimen
elicit
specif
cell
mucosa
small
intestin
fig
tcell
respons
detect
compart
vaccin
regimen
fig
compart
mean
frequenc
tcell
respons
compar
vaccin
regimen
compris
adenovir
vector
ie
aa
aapp
ppaa
candid
vaccin
macaqu
mean
respons
induc
regimen
gener
higher
induc
pp
regimen
polyfunct
tcell
respons
thought
contribut
control
viral
replic
sivinfect
nhp
hivinfect
human
cell
associ
control
siv
replic
cell
implic
maintain
function
hivspecif
respons
memori
cell
antibodi
develop
prophylact
vaccin
regimen
abl
elicit
balanc
tcell
respons
consist
cell
might
therefor
offer
valuabl
contribut
antibodybas
vaccin
strategi
candid
vaccin
shown
induc
robust
polyfunct
tcell
respons
hivseroneg
volunt
patient
art
lower
level
respons
subject
present
studi
nhp
mice
candid
vaccin
macaqu
aim
assess
immunogen
function
cmi
respons
induc
heterolog
primeboost
regimen
use
adjuv
protein
vaccin
chimpanze
recombin
adenovir
vector
simian
vector
use
base
low
preval
human
capac
adenovir
vector
gener
elicit
potent
tcell
respons
data
gener
nhp
model
could
facilit
extrapol
clinic
set
murin
data
allow
exploratori
character
anatom
local
respond
cell
induc
differ
immun
regimen
result
show
nhp
heterolog
primeboost
regimen
induc
polyfunct
tcell
respons
ii
prime
boost
increas
polyfunction
frequenc
tcell
respons
elicit
tcell
respons
mainli
driven
influenc
prime
boost
seen
cytokin
express
profil
respond
cell
iii
four
antigen
recogn
vaccineinduc
cell
iv
approxim
half
vaccin
antigenspecif
tcell
respons
exhibit
em
phenotyp
v
mice
tcell
respons
detect
mucos
system
anatom
compart
tcell
respons
primarili
driven
accord
clinic
data
show
vaccin
induc
predominantli
tcell
respons
human
fact
potent
enhanc
tcell
respons
demonstr
variou
clinic
studi
rang
antigen
review
contrast
vaccin
antigenspecif
tcell
respons
specif
tcell
respons
detect
recipi
compar
macaqu
tcell
respons
antigen
support
observ
made
replicationincompet
simian
adenovir
vector
express
siv
antigen
preclin
model
taken
togeth
heterolog
primeboost
regimen
allow
balanc
respons
cell
two
candid
vaccin
act
complementarili
rather
synergist
one
administr
magnitud
hivspecif
tcell
respons
compar
observ
one
administr
siv
antigenexpress
vector
macaqu
recent
studi
howev
second
immun
tcell
respons
measur
current
studi
appear
less
potent
respons
observ
heterolog
second
immun
vector
ref
potenti
use
altern
adc
vector
ref
circumv
induct
lowlevel
adenovir
vectorspecif
nab
respons
may
present
immun
studi
boost
poxvirusbas
vector
mva
nyvac
adc
vector
prime
also
shown
effici
increas
frequenc
insertspecif
cell
nhp
mice
adc
vector
gener
appear
induc
compar
magnitud
hivspecif
cell
howev
respons
differ
term
memori
phenotyp
cytokin
express
profil
higher
level
function
exhaust
rel
high
proport
singl
cytokineexpress
cell
vaccin
adenovir
vector
particularli
singl
administr
may
gener
immunogen
nhp
mice
compar
mva
vector
dna
vaccin
requir
multipl
administr
induc
potent
tcell
respons
howev
use
primeboost
dna
primenyvac
boost
regimen
shown
induc
robust
hivspecif
tcell
respons
macaqu
magnitud
compar
observ
vector
present
studi
though
magnitud
induc
tcell
respons
tend
lower
one
obtain
adjuv
protein
current
studi
lastli
studi
sequenc
vaccin
administr
impact
magnitud
observ
respons
persist
month
post
last
vaccin
candid
vaccin
administ
individu
abl
induc
polyfunct
tcell
respons
moreov
administ
heterolog
primeboost
schedul
prime
boost
alter
immun
profil
domin
singl
cytokineexpress
cell
increas
frequenc
polyfunct
cell
express
combin
andor
encourag
sinc
hiv
patient
control
statu
shown
higher
proport
gagspecif
cell
produc
cytokin
hiv
patient
categori
polyfunct
hivspecif
cell
associ
longterm
nonprogress
diseas
low
viral
load
human
predomin
cell
among
tcell
respons
found
present
studi
line
previou
clinic
result
product
predomin
common
featur
adjuv
protein
vaccin
also
link
favor
clinic
outcom
hivinfect
patient
associ
memori
cell
well
tcell
prolifer
differenti
although
antigen
recogn
specif
cytokineexpress
tcell
respons
mainli
direct
rt
distribut
antigen
specif
well
cytokin
express
profil
tcell
respons
agreement
featur
tcell
respons
seen
human
recipi
although
predomin
rt
respons
could
function
respect
length
antigen
sequenc
andor
associ
number
epitop
contain
therein
result
still
promis
sinc
tcell
specif
distribut
seen
among
respons
hivinfect
patient
spontan
viral
control
illustr
import
gagspecif
respons
frequenc
polyfunct
gagspecif
cell
found
highli
associ
abil
cell
control
siv
viremia
six
month
last
immun
induc
memori
cell
mainli
cm
bias
approxim
half
induc
memori
cell
maintain
activ
em
bias
phenotyp
similar
result
found
gagexpress
chimpanze
adenovir
vector
primeboost
regimen
nhp
induc
balanc
em
cm
cell
em
cell
respons
shown
associ
control
pathogen
siv
challeng
evid
viral
clearanc
therefor
vaccin
elicit
persist
specif
em
bias
respons
particularli
mucos
site
may
abl
contribut
initi
viral
control
howev
cm
cell
limit
immedi
effector
function
known
replenish
em
cell
pool
dynam
turnov
may
therefor
also
contribut
protect
inde
elit
control
maintain
minim
tcell
respons
highli
function
broadspectrum
cm
cell
detect
shown
suppress
hiv
vitro
mice
primeboost
regimen
gener
tcell
respons
across
multipl
system
mucos
anatom
compart
line
studi
use
differ
adenovir
vector
mice
nhp
respons
higher
genit
tract
mucosa
compar
intestin
mucosa
system
organ
liver
spleen
also
observ
adenovir
vector
mainten
robust
mucos
tcell
respons
import
viral
control
nhp
well
human
associ
favour
clinic
outcom
furthermor
due
haematogen
viral
dissemin
mainten
function
tcell
respons
local
system
compart
also
consid
import
infect
control
nhp
whether
find
mice
would
translat
nhp
human
remain
determin
howev
distribut
mucos
cellular
respons
among
anatom
compart
im
immun
ad
vectorbas
siv
vaccin
previous
shown
compar
two
model
hivspecif
bind
antibodi
respons
detect
group
seem
driven
two
vaccin
line
potent
hivspecif
bind
antibodi
respons
seen
sever
clinic
studi
either
hiv
antigenexpress
adenovector
recent
find
indic
envelopespecif
nonneutr
igg
antibodi
may
import
protect
hiv
simianhuman
immunodefici
viru
acquisit
suggest
prophylact
vaccin
also
contain
envelopebas
antigen
therefor
develop
altern
primeboost
approach
chimpanze
adenovir
vector
adjuv
protein
combin
strategi
aim
induc
envelopespecif
antibodi
might
merit
explor
heterolog
primeboost
regimen
candid
vaccin
induc
balanc
polyfunct
tcell
respons
hivspecif
igg
antibodi
peripher
blood
nhp
local
tcell
respons
variou
mucos
system
compart
mice
suggest
primeboost
regimen
combin
adjuv
protein
lowseropreval
simian
adenovir
vector
may
repres
attract
vaccin
strategi
prophylact
vaccin
vaccin
candid
describ
previous
briefli
antigen
recombin
fusion
protein
express
escherichia
coli
contain
subtyp
b
antigen
rt
nef
brulai
formul
liposomebas
b
adjuv
system
elsewher
articl
refer
contain
mpl
quillaja
saponaria
fraction
antigen
inc
wholli
own
subsidiari
agenu
inc
per
human
dose
gener
adenoviru
vector
base
atcc
sequenc
insert
introduc
molecular
clone
control
cmv
ie
promot
express
fusion
protein
consist
subtyp
b
antigen
protein
order
gagrtnef
grn
recombin
replicationincompet
virus
produc
transfect
hek
packag
cell
purifi
cscl
gradient
nhp
studi
carri
strict
accord
european
regul
regard
protect
anim
use
experiment
purpos
particular
council
direct
studi
initi
protocol
nhp
studi
submit
ethic
review
approv
institut
ethic
committe
centr
intern
de
toxicologi
cit
evreux
franc
associ
assess
accredit
laboratori
anim
care
aaalac
accredit
review
document
ethic
committe
databas
refer
number
sixteen
femal
male
chineseorigin
purposebr
rhesu
macaqu
macaca
mulatta
approxim
month
old
hous
cit
dedic
primat
unit
temperatur
humid
lightdark
cycl
h
anim
hous
custombuild
grouphous
cage
h
volum
grid
floor
animalscag
macaqu
free
access
tap
water
receiv
daili
ration
g
owm
e
sqc
short
expand
diet
dietex
franc
addit
fruit
andor
veget
plastic
toy
given
daili
enrich
mean
bodi
weight
kg
rang
kg
male
kg
rang
kg
femal
macaqu
alloc
four
group
male
femal
base
level
nonspecif
tcell
respons
observ
ic
assay
prevaccin
ensur
balanc
distribut
among
group
receiv
two
intramuscular
im
inject
andor
p
follow
homolog
pp
aa
heterolog
ppaa
aapp
primeboost
regimen
indic
tabl
inject
administ
intramuscularli
contain
viral
particl
vp
andor
protein
formul
monkey
bled
without
anaesthesia
sever
timepoint
post
immun
tabl
moribund
femal
ppaa
group
prematur
sacrif
exsanguin
day
sedat
ketamin
hydrochlorid
anaesthesia
thiopent
anim
show
dehydrat
hypoact
mark
liquid
fece
day
thin
appear
hypothermia
ventral
recumb
prostrat
enophtalmu
halfclos
eye
day
sacrific
coprolog
show
presenc
trichuri
trichiura
egg
observ
quantiti
explain
clinic
symptom
subsequ
macroscop
microscop
postmortem
examin
indic
anim
poor
health
condit
causal
relat
immun
conclus
reveal
caus
death
monkey
euthan
human
overdos
anesthet
complet
experi
mous
studi
carri
strict
accord
european
regul
particular
council
direct
regard
protect
anim
use
experiment
purpos
gsk
anim
facil
rixensart
belgium
aaalacaccredit
gsk
institut
ethic
committe
review
protocol
approv
number
femal
mice
hybrid
balbc
mice
age
week
studi
initi
anim
free
access
water
mainten
diet
consist
aaalac
global
enrich
program
environ
includ
nest
materi
envirodri
social
hous
appli
mice
randomli
alloc
group
n
receiv
two
four
intramuscular
inject
gastrocnemian
muscl
contain
protein
formul
p
andor
vp
inject
given
accord
follow
immun
schedul
pp
aa
day
aapp
ppaa
day
fifth
group
n
receiv
salin
control
seven
day
last
immun
mice
euthan
barbitur
acid
deriv
order
collect
organ
liver
spleen
small
intestin
genit
tract
peripher
blood
mononuclear
cell
pbmc
isol
blood
sampl
use
lymphoprep
axisshield
densiti
gradient
centrifug
g
min
frozen
fetal
calf
serum
fc
gibco
dimethyl
sulfoxid
dmso
cryopreserv
cell
express
andor
detect
use
intracellular
cytokin
stain
ic
flow
cytometri
pbmc
thaw
complet
rpmi
medium
sigma
supplement
fc
plate
round
bottom
plate
cellswel
cell
stimul
vitro
overnight
co
medium
alon
neg
control
either
staphylococc
enterotoxin
b
sigma
posit
control
peptid
pool
overlap
amino
acid
cover
full
sequenc
individu
sequenc
rt
nef
antigen
cultur
contain
costimulatori
molecul
bd
bioscienc
hour
stimul
brefeldin
bd
pharmingen
ad
overnight
cell
wash
flow
buffer
phosphatebuff
salin
pb
fc
azid
stain
min
monoclon
antibodi
mab
specif
surfac
molecul
clone
clone
blue
clone
antibodi
bd
bioscienc
usa
cell
wash
flow
buffer
permeabil
cytofixcytoperm
solut
bd
bioscienc
min
wash
permwash
buffer
bd
bioscienc
stain
hour
mab
specif
intracellular
cytokin
ie
clone
clone
clone
clone
antibodi
bd
bioscienc
cell
wash
permwash
buffer
resuspend
cellfix
solut
bd
bioscienc
mab
use
memori
tcell
phenotyp
analysi
includ
clone
clone
clone
clone
blue
clone
clone
clone
antibodi
bd
bioscienc
stain
cell
analyz
flow
cytometri
use
lsrii
flow
cytomet
facsdiva
bd
bioscienc
spice
softwar
tree
star
inc
version
ic
result
present
backgroundsubtract
percentag
cell
express
combin
andor
tcell
respons
consid
posit
antigenspecif
respons
greater
equal
cutoff
valu
cutoff
valu
calcul
basi
maximum
valu
round
superior
hundredth
among
th
percentil
cytokineexpress
cell
follow
stimul
peptid
prevaccin
time
point
cell
cell
bind
antibodi
respons
monkey
serum
sampl
assess
use
enzymelink
immunosorb
assay
elisa
briefli
plate
coat
antigen
pb
left
overnight
block
h
satur
buffer
pb
tween
bsa
nc
serum
sampl
serial
dilut
twelv
dilut
satur
buffer
incub
plate
h
wash
step
tween
pb
secondari
horseradish
peroxidaselabel
mous
antihuman
igg
antibodi
stratech
incub
plate
dilut
h
antibodi
bind
reveal
addit
substrat
biorad
reaction
stop
addit
h
optic
densiti
record
nm
use
emax
micropl
reader
molecular
devic
midpoint
titr
calcul
reciproc
dilut
maxim
bind
achiev
use
softmax
pro
softwar
molecular
devic
gmt
calcul
sera
nonrespond
anim
assign
valu
correspond
half
lowest
dilut
use
serial
serum
dilut
ie
titr
liver
spleen
mucosa
genit
tract
small
intestin
mice
collect
day
post
last
dose
small
intestin
specimen
wash
pb
supplement
fc
cut
small
piec
incub
complet
rpmi
medium
sigma
supplement
fc
mm
edta
time
min
vigor
shake
everi
min
medium
renew
remov
epitheli
cell
third
incub
specimen
wash
twice
fresh
medium
incub
complet
rpmi
supplement
iuml
liberas
mgml
dnase
roch
fc
min
vigor
shake
digest
sampl
filter
cell
strainer
wash
fresh
rpmi
medium
supplement
fc
per
group
pool
sampl
contain
cell
anim
form
cell
sampl
resuspend
percol
ge
healthcar
layer
percol
gradient
layer
centrifug
rpm
min
room
temperatur
lymphocyt
intestin
mucos
tissu
collect
interfac
wash
twice
rpmi
medium
supplement
fc
genit
tract
cut
small
piec
digest
two
serial
incub
min
complet
rpmi
medium
supplement
fc
iuml
liberas
mgml
dnase
vigor
shake
end
incub
period
supernat
filter
cell
strainer
wash
fresh
rpmi
medium
supplement
fc
cell
two
incub
period
pool
ultim
cell
digest
genit
tract
pool
result
pool
sampl
per
group
cell
sampl
resuspend
percol
lymphocyt
isol
percol
gradient
describ
process
liver
perfus
remov
blood
liver
specimen
cut
small
piec
place
gentlemac
c
tube
miltenyi
biotech
complet
rpmi
medium
supplement
fc
iuml
liberas
mgml
dnase
tissu
dissoci
use
gentlemac
dissoci
end
program
tube
incub
min
vigor
shake
complet
digest
sampl
filter
cell
strainer
wash
fresh
rpmi
medium
supplement
fc
cell
liver
pool
result
pool
sampl
per
group
resuspend
percol
lymphocyt
isol
percol
gradient
describ
two
spleen
per
group
collect
process
separ
leukocyt
spleen
biopsi
isol
complet
rpmi
medium
use
potter
tissu
grinder
homogen
tissu
filter
filter
bd
falcon
cell
suspens
resuspend
ml
complet
rpmi
centrifug
rpm
min
pellet
resuspend
ml
complet
rpmi
centrifug
rpm
min
resuspend
ml
rpmi
supplement
fc
process
assay
local
cellmedi
respons
mice
tcell
respons
liver
spleen
mucosa
vagin
tract
small
intestin
mice
assess
day
post
last
dose
fresh
cell
plate
round
bottom
plate
nunc
thermo
fisher
approxim
cellswel
leukocyt
stimul
vitro
hour
co
peptid
pool
overlap
amino
acid
cover
full
sequenc
left
unstimul
presenc
bd
bioscienc
brefeldin
ad
hour
bd
bioscienc
plate
transfer
left
overnight
next
cell
stain
analyz
use
ic
assay
cell
transfer
vbottom
plate
nunc
thermo
fisher
centrifug
g
min
resuspend
flow
buffer
pb
fc
azid
contain
antimous
clone
min
flow
buffer
contain
blue
clone
clone
antibodi
final
dilut
bd
bioscienc
ad
min
cell
pellet
g
statist
analysi
sa
version
use
perform
statist
analysi
sampl
size
calcul
nhp
studi
base
inform
gather
previou
studi
consid
alpha
risk
standard
deviat
group
estim
animalsgroup
ratio
group
intens
tcell
respons
could
significantli
observ
power
analysi
result
mean
log
transform
tcell
frequenc
antibodi
titer
differ
timepoint
compar
group
use
satterthwait
test
assum
unequ
varianc
proport
cell
express
one
two
three
differ
cytokin
individu
anim
normal
total
group
mean
proport
compar
use
fisher
exact
test
signific
level
p
use
support
inform
tabl
geometr
mean
confid
interv
tcell
respons
macaqu
pdf
tabl
cytokin
express
profil
tcell
respons
individu
macaqu
pdf
tabl
geometr
mean
confid
interv
tcell
respons
macaqu
pdf
tabl
cytokin
express
profil
tcell
respons
individu
macaqu
pdf
tabl
antigen
target
tcell
respons
individu
macaqu
week
post
last
immun
pdf
tabl
phenotyp
memori
cell
cell
individu
macaqu
month
post
last
immun
pdf
tabl
phenotyp
memori
cell
cell
individu
macaqu
month
post
last
immun
pdf
tabl
humor
respons
antigen
individu
macaqu
pdf
